Profund Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Profund Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-34,896	Closed	-$343K	–	1101
2023 Q1	$343K	Buy	+34,896	New	+$595K	0.02%	654

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Profund Advisors's INO Position: Q2 2023 in Review

Profund Advisors sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 34,896 shares — an estimated $343K sold.

Profund Advisors first reported a position in INO in Q1 2023 and held it in 1 quarter. The position peaked at $343K in Q1 2023. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

Profund Advisors reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Profund Advisors sold 34,896 Inovio Pharmaceuticals shares in Q2 2023, an estimated $343K.
Profund Advisors first reported a position in Inovio Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Profund Advisors's Inovio Pharmaceuticals position peaked at $343K in Q1 2023.
133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Profund Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.